Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP584 | DOI: 10.1530/endoabs.90.EP584

ECE2023 Eposter Presentations Endocrine-related Cancer (80 abstracts)

Patient-derived three-dimensional model of papillary thyroid cancer for personalized medicine and testing of novel therapies

Daria Petrova 1 , Asya Bastrich 1 , Zaur Abilov 1 , Ekaterina Bondarenko 2 , Liliya Urusova 2 , Petr Nikiforovich 1 , Dmitry Belcevich 2 , Svetlana Pylina 1 , Anna Eremkina 2 , Ekaterina Kim 1 & Natalia Mokrysheva 2


1Endocrinology Research Center, National Center for Personalized Medicine of Endocrine Diseases, Moscow, Russia; 2Endocrinology Research Center, Moscow, Russia


Introduction: Over the last decades, there has been a significant increase in the incidence of thyroid cancer. Papillary thyroid cancer (PTC) is the most common histopathological type with often a favorable prognosis. Conventional therapies include surgical resection, adjuvant therapy with radioactive iodine, and suppressive therapy with thyroid hormones. However, the prognosis for iodine-resistant/refractory thyroid cancers or the advanced metastatic cancer is less favorable. We present the patient-derived three-dimensional (3D) model of PTC, which can be used to test novel therapies.

Results: 3D cancer organ-like cultures (organoids) can be obtained from tumor resections or biopsies, propagated in vitro, frozen and thawed at any time. Organoid culture preserves genetic and cellular heterogeneity and allows determining individual responses of a tumor to drug therapies. To complement the existing protocols (Sondorp et al., 2020; Chen et al, 2021), we have developed an effective patient-derived 3D PTC models both for primary tumors and metastases. Pretreatment of cancerous tissue, culture medium, extracellular matrix and method of passaging are crucial for successful establishment of stable organoid cultures. Optimization of all the stages resulted in obtaining self-sustaining PTC organoid lines. Immunohistochemical analyses (anti-Ki-67, anti-TTF-1, anti-Thyroglobulin) and H&E staining of organoids and original tumor confirmed the malignant nature of the organoids, their heterogeneity and proved that PTC organoids recapitulate features (such as papillary, follicular or cystic structures) of the parental tumor tissue. The analyses were performed after at least three passages of the PTC organoid lines in vitro.

Conclusion: The presented model can be used for personalized medicine and development of optimal therapies for PTC.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.